Evidence map›Paper›PMID 36938552›Full record

ReviewActa clinica Croatica2022

MRI-GUIDED RADIOTHERAPY FOR PROSTATE CANCER: A NEW PARADIGM.

Jure Murgić, Marin Gregov, Iva Mrčela, Mirjana Budanec, Marco Krengli, Ana Fröbe, Pierfrancesco Franco

Open access · diamondAbstract readReview
In one paragraph

Review in Acta clinica Croatica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jure MurgićDepartment of Oncology and Nuclear Medicine, Sestre milosrdnice University Hospital Center, Vinogradska 29, 10000 Zagreb, Croatia.
Marin GregovDepartment of Medical Physics, Sestre milosrdnice University Hospital Center, Vinogradska 29, 10000 Zagreb, Croatia.
Iva MrčelaDepartment of Medical Physics, Sestre milosrdnice University Hospital Center, Vinogradska 29, 10000 Zagreb, Croatia.
Mirjana BudanecDepartment of Medical Physics, Sestre milosrdnice University Hospital Center, Vinogradska 29, 10000 Zagreb, Croatia.
Marco KrengliDepartment of Translational Medicine, University of Eastern Piedmont, 28100 Novara, Italy.
Ana FröbeDepartment of Oncology and Nuclear Medicine, Sestre milosrdnice University Hospital Center, Vinogradska 29, 10000 Zagreb, Croatia.
Pierfrancesco FrancoDepartment of Translational Medicine, University of Eastern Piedmont, 28100 Novara, Italy.
University Hospital Centre Zagreb · HR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiotherapy is one of the key treatment modalities for primary prostate cancer. During the last decade, significant advances were made in radiotherapy technology leading to increasing both physical and biological precision. Being a loco-regional treatment approach, radiotherapy requires accurate target dose deposition while sparing surrounding healthy tissue. Conventional radiotherapy is based on computerized tomography (CT) images both for radiotherapy planning and image-guidance, however, shortcomings of CT as soft tissue imaging tool are well known. Nowadays, our ability to further escalate radiotherapy dose using hypofractionation is limited by uncertainties in CT-based image guidance and verification. Magnetic resonance imaging (MRI) is a well established imaging method for pelvic organs. In prostate cancer specifically, MRI accurately depicts prostate zonal anatomy, rectum, bladder, and pelvic floor structures with previously unseen precision owing to its sharp soft tissue contrast. The advantages of including MRI in the clinical workflow of prostate cancer radiotherapy are multifold. MRI allows for true adaptive radiotherapy to unfold based on daily MRI images taken before, during and after each radiotherapy fraction. It enables accurate dose escalation to the prostate and intraprostatic tumor lesions. Technically, MRI high-strength magnetic field and linear accelerator high energy electromagnetic beams are hardly compatible, and important efforts were made to overcome these technical challenges and integrate MRI and linear accelerator into one single treatment device, called MRI-linac. Different systems are produced by two leading vendors in the field and currently, there are around 100 MRI-linacs worldwide in clinical operations. In this narrative review paper, we discuss historical perspective of image guidance in radiotherapy, basic elements of MRI, current clinical developments in MRI-guided prostate cancer radiotherapy, and challenges associated with the use of MRI-linac in clinical practice.

Indexed as

Prostatic NeoplasmsRadiotherapy, Image-GuidedHumansMagnetic Resonance ImagingMaleRadiotherapy Planning, Computer-AssistedTomography, X-Ray Computedimage-guided radiotherapyMR-guided radiotherapyMR-linaconline adaptive radiotherapyprostate cancer

Identifiers

PMID36938552
PMCPMC10022406
OpenAlexW4327896733

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.